Hantz Financial Services, Inc. Halozyme Therapeutics, Inc. Transaction History
Hantz Financial Services, Inc.
- $6.19 Billion
- Q2 2025
A detailed history of Hantz Financial Services, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 134,780 shares of HALO stock, worth $8.9 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
134,780
Previous 151,784
11.2%
Holding current value
$8.9 Million
Previous $9.69 Million
27.61%
% of portfolio
0.11%
Previous 0.17%
Shares
4 transactions
Others Institutions Holding HALO
# of Institutions
605Shares Held
127MCall Options Held
408KPut Options Held
388K-
Black Rock Inc. New York, NY17.6MShares$1.16 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$808 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$392 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$229 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$224 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.2B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...